Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271690 | 0.91 | IDO1 (0.45) | IDO1LOXL2NCF1HTR1AADRA1D | |
| SCHEMBL23716938 | 0.90 | CNR2 (0.46) | IDO1LOXL2NCF1HTR1AADRA1D | |
| SCHEMBL21834887 | 0.88 | CNR2 (0.47) | IDO1LOXL2NCF1HTR1AADRA1D | |
| SCHEMBL21834885 | 0.88 | CNR2 (0.47) | IDO1LOXL2NCF1HTR1AADRA1D | |
| SCHEMBL4313522 | 0.88 | IDO1 (0.49) | IDO1NCF1HTR1AHTR1DHTR1B | |
| SCHEMBL21816316 | 0.86 | LOXL2 (0.50) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL31175311 | 0.86 | LOXL2 (0.50) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL2333830 | 0.85 | NCF1 (0.51) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL23412842 | 0.84 | NCF1 (0.57) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL23412358 | 0.84 | NCF1 (0.57) | LOXL2NCF1HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| WO-2007081091-A1 | RHODANDSE DERIVARIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-19 | — | — | WO | disclosed |
| EP-0512352-B1 | Substituted carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 1996-03-27 | — | — | EP | disclosed |
| US-5344843-A | Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders | HOFFMAN-LA ROCHE INC. (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | IDO1 2131/4885LOXL2 3355/4885NCF1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.